Medicine name and product details
Tirzepatide (Mounjaro, Eli Lilly) is a long-acting dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide‑1 (GLP‑1) receptor agonist for subcutaneous injection with a pre-filled pen. It is licensed for weight management as an adjunct to a reduced-calorie diet and increased physical activity in adults with specified initial body mass index (BMI). The details of the licensed indication and dosage schedule are available in the summary of product characteristics for tirzepatide.